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S U M M A R Y
Objectives: Invasive zygomycosis is a rare fungal opportunistic disease with a high morbidity and
mortality rate, predominantly affecting immunosuppressed patients. Presented herein is our
investigation of the epidemiological factors associated with an increasing incidence of the disease at
the University of Geneva Hospitals, Geneva, Switzerland, over the past ﬁve years.
Methods: This was a retrospective study of the clinical charts andmicrobiology records of patientswith a
positive culture for zygomycetes, to evaluate predisposing factors and epidemiological characteristics.
Results: Three of 19 proven/probable invasive infections were diagnosed during 1989–2003, and 16
during 2003–2008. While the number of positive isolates for zygomycetes remained mainly stable, the
ratio between invasive infections and colonized patients increased after the introduction of voriconazole
and caspofungin in 2003 at our institution (p < 0.001). All cases were unrelated and no nosocomial
source of exposure or seasonal aggregation was identiﬁed. The increase in cases was coincident with an
incremented use of voriconazole and caspofungin, and with an increased number of immunosuppressed
patients, especially allogeneic bone marrow transplant recipients.
Conclusions: Invasive zygomycosis is an emerging infection at our center and is probably related to an
increase in immunosuppressed patients and the wide use of newer antifungals. Changes in antifungal
drug prophylaxis and treatment prescription may help to control this emergence.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Invasive zygomycosis is a rare opportunistic fungal diseasewith
high morbidity and mortality rates, predominantly affecting
immunosuppressed patients. In most published series of patients
with hematologic malignancies, it represents the third most
common opportunistic mold infection after invasive aspergillosis
and invasive fusariosis.1 An increasing incidence has recently been
described in some centers in the USA, particularly among
allogeneic bone marrow transplantation (BMT) recipients. This
is coincident with the widespread use of newer antifungal drugs,
such as voriconazole and caspofungin, which are highly active
against most molds, but not against zygomycetes.2–9 However, no
such increase has been observed or conﬁrmed in other countries,10
and any correlation between the occurrence of this disease and
antifungal use remains controversial.§ The preliminary results of this study were presented at the 48th Annual
Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual
Meeting of the Infectious Diseases Society of America,Washington, DC, October 25–
28, 2008, abstract M-726.
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doi:10.1016/j.ijid.2009.11.024During 2008, six cases of invasive zygomycosis were diagnosed
at our institution, representing an important increase in the annual
number of cases usually observed. We conducted a retrospective
analysis of the local epidemiology of zygomycosis to explain this
phenomenon and to implement measures to control the emer-
gence of the disease.
2. Materials and methods
The University of Geneva Hospitals is a tertiary teaching
hospital with 1600 acute care beds and more than 40 000
admissions each year. It comprises all surgical and internal
medicine services, as well as a bone marrow and solid organ
transplant unit.
A retrospective analysis was conducted of the clinical charts of
all patients with the isolation of zygomycetes documented both in
the microbiology laboratory database and pathology reports since
1989. Cases were categorized as either invasive infection (proven/
probable) according to the EuropeanOrganisation for Research and
Treatment of Cancer (EORTC) criteria, or colonization (no signs of
active infection, no treatment administered). Patient demo-
graphics, species involved, predisposing factors, clinical presenta-
tion, antifungal prophylaxis, treatment, outcome, and follow-upses. Published by Elsevier Ltd. All rights reserved.
Figure 2. Invasive zygomycosis incidence and antifungal consumption, 1989–2008,
University of Geneva Hospitals.
Figure 3.Hospital admissions and allogeneic bonemarrow transplantations, 2002–
2008, University of Geneva Hospitals.
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made of the ratio between invasive infection and colonization, the
incidence among hospital admissions, and the incidence in BMT
recipients before and after the introduction of voriconazole and
caspofungin. The Chi-square test or Fisher’s exact test was used to
estimate the statistical signiﬁcance, and values of p < 0.05 were
considered to be signiﬁcant.
Identiﬁcation of zygomycetes in the microbiology laboratory
was performed by standard culture in Sabouraud medium and
morphologic examination. Additionally, since 2001, species
identiﬁcation has been available by DNA sequence analysis.
Invasive infection cases were epidemiologically studied to analyze
any cluster association. Surveillancemicrobiology reports from the
pharmacy production area were also analyzed to exclude a
nosocomial source of infection through the administration of
medication.
3. Results
Zygomycete species were isolated in clinical specimens from 55
patients between January 1989 and December 2008. Methods for
the culture and identiﬁcation of zygomycetes in the microbiology
laboratory did not change during the study period, apart from the
availability of molecular biology diagnostic techniques from 2001.
Thirty-six patients (65%) were considered as colonized without
any evidence of invasive disease and did not receive any treatment.
The most prevalent colonized sites were the nasal sinuses and
upper respiratory tract. The total number of positive isolates
(invasive infection plus colonization) per year remained mainly
stable, but the relationship between invasive infection and
colonization increased progressively over the studied period
(three of 31 total isolates until 2003, and 16 of 24 since 2003;
p < 0.001) (Figure 1). The newer antifungal drugs, voriconazole
and caspofungin, werewidely introduced in our center in 2003 and
their use in antifungal treatment and prophylaxis has markedly
increased since then (Figure 2). The incidence of other mold
opportunistic infections remained stable during the study period
with six to nine proven/probable cases of invasive aspergillosis per
year and zero to one case of invasive fusariosis per year.
The annual number of hospital admissions to our institution has
remained stable over the past few years, whereas the number of
BMT recipients has increased (Figure 3). The highest incidence of
invasive zygomycosis since the introduction of voriconazole and
caspofungin was evidenced in 2008, with one case per 7499
admissions and one case per 7.6 allogeneic BMT. Three cases were
conﬁrmed before 2003 (0.57/100 000 admissions per year) and 16
after 2003 (6.3/100 000 per year, p < 0.0000). Before 2003, one caseFigure 1. Patients with zygomycete colonization and infection, 1989–2008,
University of Geneva Hospitals.was conﬁrmed in 341 BMT performed, whereas there were ﬁve
cases in 197 BMT after 2003 (p < 0.03). There was no seasonal
aggregation for invasive infections, although nine cases (47%) were
diagnosed between July and September.
All zygomycosis infections were clinically analyzed (Table 1).
The demographic characteristics of patients with invasive zygo-
mycosis were: median age 52 years (range 10–77 years), 68%
women. The most frequently isolated genus was Rhizopus (42%),
followed by Rhizomucor (32%), Absidia (16%), Cunninghamella
(5%), and Mucor (5%). No species was found to be predominant at
any period of time.
The most frequent predisposing conditions were hematologic
malignancies (42%). Of these, 75% of cases were allogeneic BMT
recipients and 50% were neutropenic at the time of diagnosis.
Other predisposing conditions included high-dose steroid therapy
(21%), solid organ transplantation (16%), diabetes mellitus (16%),
HIV infection (10.5%), and trauma (10.5%). Four BMT recipients
(21%) with hematologic malignancies developed a graft-versus-
host disease. The body sites of invasive zygomycosis infection
were: pulmonary (42%), rhinosinusal (10.5%), and rhinocerebral,
renal, hepatic and cutaneous (5% each); the zygomycosis was
considered disseminated in 26% of cases.
Prior to the diagnosis of invasive zygomycosis, nine patients
(47%) received antifungal prophylaxis for a median duration of 23
days (range 4–300 days). Of these, seven (78%) received
voriconazole, three in combination or sequentially with caspo-
fungin (Table 2). Seven (78%) patients were under antifungal
prophylaxis after 2003 at the same time as the diagnosis of
invasive zygomycosis. Three patients had proven/probable inva-
sive aspergillosis according to the EORTC criteria and four other
Table 1
Features of the 19 patients with an invasive zygomycosis infection
Patient Year Gender Age Predisposing factor Clinical
presentation
Genus Surgery Previous
antifungal
drugs
Antifungal
treatment
Outcome
1 1991 M 44 SOT Pulmonary Absidia No No AmphB deox Death
2 1992 M 34 HIV-AIDS Renal Absidia No Fluc AmphB deox Death
3 2000 M 35 Hematologic malignancya,b Disseminated Rhizopus No No AmphB deox/
LipoAMB
Death
4 2003 M 55 Trauma, high-dose steroids Rhinosinusal Absidia Yes No AmphB deox/
LipoAMB
+Posac
Survival
5 2003 F 41 Hematologic malignancya,b Disseminated Rhizomucor No Fluc No treatment Death
6 2003 F 47 SOT Hepatic Rhizopus Yes No AmphB deox/
LipoAMB
Survival
7 2003 F 74 DM, high-dose steroids Rhinosinusal Rhizopus Yes No AmphB deox/
LipoAMB
Survival
8 2005 F 10 Hematologic malignancya,b Pulmonary Cunninghamella Yes AmphB deox,
Voric, Casp
LipoAMB+Posac Death
9 2006 F 53 Trauma Cutaneous Rhizomucor Yes No Posac Survival
10 2006 F 45 Hematologic malignancy Disseminated Rhizopus Yes Voric, Casp LipoAMB+Posac Survival
11 2007 F 55 Renal insufﬁciency,
high-dose steroids
Pulmonary Rhizopus No No Posac Death
12 2007 F 77 Lung cancer Pulmonary Rhizopus No No Posac Death
13 2007 M 45 HIV-AIDS, DM Rhinocerebral Rhizopus Yes No LipoAMB+Posac Survival
14 2008 F 63 Hematologic malignancya Pulmonary Rhizomucor No Voric No treatment Death
15 2008 F 65 SOT, high-dose steroids, DM Pulmonary Rhizomucor No Voric Posac Survival
16 2008 F 52 Hematologic malignancya,b Disseminated Rhizomucor No Voric, Casp No treatment Death
17 2008 F 64 Liver cirrhosis Pulmonary Rhizopus No No No treatment Death
18 2008 F 64 Hematologic malignancy Pulmonary Rhizomucor No Voric LipoAMB+Posac Survival
19 2008 M 18 Hematologic malignancya Disseminated Mucor No Voric LipoAMB+Posac Survival
SOT, solid organ transplantation; DM, diabetes mellitus; LipoAMB, lipid formulation of amphotericin B; AmphB deox, amphotericin B deoxycholate; Fluc, ﬂuconazole; Voric,
voriconazole; Casp, caspofungin; Posac, posaconazole.
a Bone marrow transplant recipient.
b Graft-versus-host disease.
Table 2
Previous antifungal administration in 19 patients with invasive zygomycosis
Previous antifungal use n %
No 10 53
Yes 9 47
Voriconazole 4
Voriconazole + caspofungin 2
Voriconazole + caspofungin + lipid amphotericin B 1
Fluconazole 2
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voriconazole as long-term treatment.
Invasive zygomycosis was treated with amphotericin B
deoxycholate or lipid formulations of amphotericin B in 26% of
cases, posaconazole in 21%, or a combination of amphotericin B and
posaconazole in 32%. Four patients (21%) were not treated because
the diagnosis was an autopsy ﬁnding. Surgery combined with
antifungal treatment was performed in 37% of cases. The mortality
rate was 75% in patients with antifungal treatment alone, and 14%
in patients receiving a combination of antifungal treatment and
surgery.
Cases were not related, as no patient with invasive zygomycosis
was hospitalized in the same room or unit at the same time. No
positive culture for zygomycetes was found in the routine culture
of the medication production area at the pharmacy during the
study period. Moreover, it is institutional policy to destroy all the
ongoing drug production in the pharmacy when a culture is
positive for any microorganism in the sterile zone.
4. Discussion
The results of this study demonstrate that invasive zygomycosis
is an emerging infection in our institution. Until now, the disease
has been more frequently reported in centers in the USA with ahigh number of patients with hematologic malignancies2–9 than in
general European centers.10 The emergence of mold infections is
multifactorial and may involve more intense immunosuppression,
a prolonged survival rate in patients with previously fatal diseases
(which increases the time of exposure to a fungal pathogen), and
selective pressure as a result of increased therapeutic and
prophylactic use of broad-spectrumantifungal agents. Zygomycete
infections are the most encountered, emerging mold disease and
have already been found to be associated with an increasing use of
voriconazole in some institutions.2–9 In a case–control study,
voriconazole prophylaxis was identiﬁed as an independent risk
factor for invasive zygomycosis in patients with hematologic
malignancies.11 Breakthrough zygomycosis infections have also
been reported in patients receiving echinocandins.12,13
In our hospital, we observed an increase in the number of cases
since 2003, concomitant to the introduction of voriconazole and
caspofungin. A similar increase in the number of BMT recipients, a
high-risk group, also occurred. This change could be related to the
prolonged survival rate of those who did not die of invasive
aspergillosis in this population, but had the selection pressure of an
Aspergillus-active antifungal drug. In a recent study, Lamaris et al.
reported an increased virulence of zygomycetes following
voriconazole exposure.14 Voriconazole exposure may partly
explain this change in the virulence of the fungus from colonizer
to pathogen in our center over time. However, this exposure must
be placed in the context of a higher number of susceptible patients.
Among patients undergoing antifungal prophylaxis at the moment
of the diagnosis of invasive zygomycosis, 78% were receiving
prophylaxis after 2003. Of these, seven were receiving oral
voriconazole as long-term suppressive therapy for suspected
aspergillosis.
Although nosocomial exposure to Aspergillus spores in con-
struction areas of hospitals has been clearly established as a risk
factor for aspergillosis, the epidemiology of exposure to zygomy-
cetes is less clear and it is considered as a community-acquired
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in a nosocomial setting appears to be very improbable, as cases
were not epidemiologically linked. No zygomycete was isolated in
the production area of the pharmacy of our institution, and this
allowed us to exclude the possibility of a nosocomial infection
transmitted through this route. A seasonal aggregation has been
suggested for invasive zygomycosis,15,16 but we did not observe
this in our study, even if there was a slight predominance (47%) of
cases between July and September.
Posaconazole is the only available oral drug active against
zygomycetes and it is considered as one of the ﬁrst-line treatments
for this disease.17–19 For patients at increased risk of breakthrough
zygomycete infections, prophylaxis with posaconazole may
constitute a valid option and this approach is being progressively
adopted in our hospital to control the emergence of these
pathogens. However, as the disease continues to be rare, the
evaluation of the results of this strategy is very difﬁcult over a short
period of time and needs further investigation. Posaconazole
prophylaxis for invasive fungal infections showed improved
efﬁcacy when compared with ﬂuconazole/itraconazole in patients
with either neutropenia20 or graft-versus-host disease.21 No case
of invasive zygomycosis was found in the posaconazole-treated
group. In patients at high risk, it may be safer to administer
antifungal prophylaxis with a broad-spectrum agent effective
against zygomycetes, rather than to treat patients once the
infection is diagnosed.22,23 Posaconazole has also been proposed as
an alternative for secondary prophylaxis of mold fungal infections
during stem cell transplantation.24 Thus, posaconazole prophylaxis
should be strongly considered for patients at high risk of
zygomycosis or undergoing prolonged therapy with voriconazole.
The retrospective nature of our single center study has some
limitations due to the rarity of the disease and the small number of
cases, therefore the design is probably too weak to deﬁnitively
prove a role of voriconazole and caspofungin as predisposing
variables. Moreover, any intervention needs a prolonged period of
time for an appropriate evaluation. It is difﬁcult to establish a
denominator for invasive zygomycosis, as it can affect very
different populations of immunocompromised patients. We
attempted to establish the relationship between the number of
hospital admissions and the number of BMT recipients, as these
patients have been found to be the most affected in centers in the
USA. In both cases, the incidence increased in our institution after
2003 (p = 0.0000 and p < 0.03 respectively) following the intro-
duction of voriconazole and caspofungin, although the difference
was less marked for BMT recipients, a patient population that has
markedly increased over the past years. In our study, however,
hemato-oncology patientswere not the only patients to develop an
invasive infection.
In conclusion, the increase of invasive zygomycosis in our
institution could be related to several factors and it is probably
multifactorial, but a temporal relationship was established with
the extended use of voriconazole and caspofungin in association
with an increase in immunocompromised patients. Although a
nosocomial source of infectionwas not identiﬁed, infection control
surveillance will continue to monitor the trends of zygomycosis
infection at our center and to evaluate the efﬁcacy of the
prophylactic policy changes.
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